NFKB1 and early-onset autosomal dominant Alzheimer disease: Adalimumab also impairs the development of Alzheimer’s disease by suppressing NF-κB, a crucial component of neuroinflammatory transcription factors, suggesting that BP-mediated inflammatory reactions might be a potential therapeutic candidate for the impairment of Alzheimer’s disease development [67].